Drugs / DA-002
last change Dec 2025 re-read 2 minutes ago

DA-002

Developed for
baldness, male pattern
Investigated by
Applied Biology, Inc. · Daniel Alain, Inc. · Follea International Limited

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06501924 Jan → Oct 2025 overdue baldness, male pattern Applied Biology, Inc. Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DA-002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06501924
Route Topical Topical Alpha 1 Agonist (GRAS)” NCT06501924